FDA has approved an expanded indication for Eli Lilly and Company’s Verzenio (abemaciclib), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
